Palo Alto Networks warns that advanced AI-powered cyberattacks could become widely accessible within months, significantly lowering the bar...

India's Q4 earnings show recovery signs, with Nifty 100 profits up 13%. However, macro headwinds like rising crude oil prices and a depreci...

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...

JP Morgan has cautioned that India’s FY27 earnings face significant risks from an extended energy and logistics shock linked to the Middle ...

As global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

HDFC Securities sees opportunity in India's recovering equity markets. The firm favors power and energy sectors, citing infrastructure grow...

Indian markets present attractive long-term investment opportunities following recent corrections, according to Nitin Raheja of Julius Baer...

Indian markets are experiencing a temporary disruption, not a fundamental shift. Bajaj Finserv AMC's Nimesh Chandan sees this as a chance t...

Bino Pathiparampil of Elara Capital discussed the strong Q1 FY25 performance in the pharma sector. Companies like Lupin and Dr Reddy's rece...

The Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS) would facilitate pharmaceutical MSMEs with proven track record to upgra...

The brokerage believes Covid-led opportunities could be a catalyst in the near term. It has a conviction on players having integrated manuf...

Citi has upgraded Dr Reddy Laboratories to ‘buy’ from ‘sell’ earlier. It has a target of Rs 3,380 on the stock.

Pharma sector stocks have been one of the worst performer on the bourses in last one year. BSE Healthcare index just risen a percent in the...

Govt is planning to set up a Rs 500-crore pharma technology upgradation fund which will facilitate cheaper loans to entities looking to upg...

Analysts are betting around 20% return from the stock in the medium term. They say the stock could double investor wealth in two years.

"If there are concerns on stocks like Ranbaxy or Cipla, they are few and far between."